林慧晶,徐德宇,王旭红,张丽丽,刘晨晨.孟鲁司特钠联合肝素钠对小儿过敏性紫癜的效果及对T细胞亚群、凝血功能的影响[J].现代生物医学进展英文版,2023,(5):927-930. |
孟鲁司特钠联合肝素钠对小儿过敏性紫癜的效果及对T细胞亚群、凝血功能的影响 |
Effect of Montelukast Sodium Combined with Heparin Sodium on Henoch-Schonlein Purpura in Children and Its Influence on T Cell Subsets and Coagulation Function |
Received:June 16, 2022 Revised:July 11, 2022 |
DOI:10.13241/j.cnki.pmb.2023.05.025 |
中文关键词: 小儿 过敏性紫癜 孟鲁司特钠 肝素钠 T细胞亚群 凝血功能 |
英文关键词: Children Henoch-Schonlein purpura Montelukast sodium Heparin sodium T cell subsets Blood coagulation function |
基金项目:江苏省扬州市科协软科学研究课题,江苏省扬州市科技计划项目(2022154) |
|
Hits: 543 |
Download times: 320 |
中文摘要: |
摘要 目的:分析孟鲁司特钠联合肝素钠对小儿过敏性紫癜的效果及对T细胞亚群、凝血功能的影响。方法:选择我院自2019年4月至2022年4月接诊的136例过敏性紫癜患儿作为研究对象,随机分为对照组和观察组,各68例。两组均在常规治疗的基础上,对照组予以肝素钠治疗,观察组予以孟鲁司特钠联合肝素钠治疗。比较两组各项临床症状的消退时间,治疗前后的外周血T细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)、凝血功能指标[纤维蛋白原(FIB)、凝血酶原时间(PT)、凝血活酶时间(APTT)];根据临床症状、体征及实验室指标的改善情况,综合评价疗效,计算两组总有效率。结果:观察组关节疼痛、便血缓解、腹痛缓解和紫癜消退的时间均短于对照组(P<0.05);观察组治疗后外周血CD3+、CD4+、CD4+/CD8+水平较对照组高,CD8+水平较对照组低(P<0.05);观察组治疗后FIB水平较对照组低,PT、APTT均长于对照组(P<0.05);观察组总有效率为95.59 %,高于对照组的79.41 %(P<0.05)。结论:孟鲁司特钠联合肝素钠能协同提高小儿过敏性紫癜的效果,调节T细胞亚群,增强免疫功能,改善凝血功能,值得临床予以重视应用。 |
英文摘要: |
ABSTRACT Objective: To analyze the effect of montelukast sodium combined with heparin sodium on children Henoch-Schonlein purpura and its influence on T cell subsets and coagulation function. Methods: A total of 136 children with allergic purpura treated in our hospital from April 2019 to April 2022 were selected and randomly divided into the control group and the observation group, with 68 cases each. Both groups were based on the conventional treatment, the control group received heparin sodium treatment, and the observation group received montelukast sodium combined with heparin sodium treatment. Compare the regression time of the clinical symptoms, the peripheral T cell subsets (CD3+, CD4+, CD8+, CD4+/CD8+), fibrinogen (FIB) (PT), prothrombin time (APTT)], and evaluate the improvement of clinical symptoms, signs and laboratory indicators, calculate the total effective rate. Results: The remission time of joint pain, hematochezia, abdominal pain and purpura in observation group were shorter than those in matched group (P<0.05) .After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in peripheral blood of the observation group were higher than those of the matched group, and the level of CD8+ was lower than that of the matched group(P<0.05). After treatment, the FIB level in the observation group was lower than that in the matched group, PT and APTT were longer than those in the matched group (P<0.05). The total effective rate of the observation group was 95.59 %, which was higher than 79.41 % of the matched group(P<0.05). Conclusion: Montelukast sodium combined with heparin sodium can synergistically improve the effect of Henoch-Schonlein purpura in children, regulate T cell subsets,enhance immune function, improve coagulation function, which is worthy of clinical attention. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|